Less Ads, More Data, More Tools Register for FREE

Pin to quick picksItaconix Plc Regulatory News (ITX)

Share Price Information for Itaconix Plc (ITX)

Share Price is delayed by 15 minutes
Get Live Data
113.50    0.00 (0.00%)
Bid:
110.00
Ask:
117.00
Spread: 7.00 (6.364%)
Market Cap: £15.31m
ITX Live PriceLast checked at - London Stock Exchange

Intraday Itaconix Plc Share Chart

First Bio-based Polymer Application Agreement

26 Jul 2017 14:00

RNS Number : 1460M
Itaconix PLC
26 July 2017
 

26 July 2017

Itaconix plc ("Itaconix")

AkzoNobel and Itaconix finalize first bio-based polymer application agreement

Itaconix has finalized the first application agreement for bio-based polymers to result from its collaboration with AkzoNobel's Specialty Chemicals business, announced earlier this year. This application agreement involves AkzoNobel's Performance Additives unit developing applications for Itaconix polymers to be used in the coatings and construction industries.

"We are pleased to be announcing the first in a series of agreements to develop these polymers for commercial use," said Peter Nieuwenhuizen, RD&I Director for AkzoNobel's Specialty Chemicals business. "Being able to incorporate polymers made from renewable bio-based raw materials will give a significant sustainability advantage for our customers and also fits closely with our own Planet Possible sustainability agenda of doing more with less."

Under the agreement, Itaconix will contribute its proprietary polymers from itaconic acid, which are obtained from sugars through fermentation. Continued Nieuwenhuizen: "In addition to applications in coatings and construction materials, bio-based polymers have the potential to be used in a range of other everyday essentials, ranging from improving water quality to cleaning and hygiene products." Nieuwenhuizen also pointed out that the collaboration with Itaconix is another example of AkzoNobel's approach to embracing open innovation to help find more sustainable solutions.

Dr. Kevin Matthews, CEO of Itaconix, added: "This is the first commercial step in our joint development agreement to collaborate on delivering valuable solutions to AkzoNobel customers with the novel performance of our polymers. We are excited to further strengthen our relationship with AkzoNobel and look forward to combining their deep application knowledge with our unique chemistries to build key product positions in these large and important markets."

 

Ends

For further information please contact:

Itaconix

+44 (0) 1244 283 500

Kevin Matthews / Rob Cridland

N+1 Singer

+44 (0) 207 496 3000

Richard Lindley / Liz Yong (Corporate Finance)

Nick Owen (Corporate Broking)

Hudson Sandler

Charlie Jack / Emily Dillon +44 (0) 207 796 4133

About Itaconix

Itaconix is developing proprietary active ingredients that meet the performance and price needs of its customers and offers them improved safety and sustainability, thereby helping to deliver on the global sustainability agenda, with particular emphasis on the Personal Care and Homecare markets.

www.itaconix.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTDMGZNLVVGNZG
Date   Source Headline
30th Mar 20217:00 amRNSFull Year Results Ended 31 December 2020
24th Mar 202111:06 amRNSSecond Price Monitoring Extn
24th Mar 202111:00 amRNSPrice Monitoring Extension
24th Mar 20217:00 amRNSNotice of Final Results and Investor Presentation
23rd Mar 20212:06 pmRNSSecond Price Monitoring Extn
23rd Mar 20212:00 pmRNSPrice Monitoring Extension
23rd Mar 202111:05 amRNSSecond Price Monitoring Extn
23rd Mar 202111:00 amRNSPrice Monitoring Extension
28th Jan 20212:06 pmRNSSecond Price Monitoring Extn
28th Jan 20212:01 pmRNSPrice Monitoring Extension
27th Jan 202111:06 amRNSSecond Price Monitoring Extn
27th Jan 202111:00 amRNSPrice Monitoring Extension
26th Jan 202111:05 amRNSSecond Price Monitoring Extn
26th Jan 202111:00 amRNSPrice Monitoring Extension
26th Jan 20217:00 amRNSTrading Update for the year ended 31 December 2020
21st Jan 202111:05 amRNSSecond Price Monitoring Extn
21st Jan 202111:01 amRNSPrice Monitoring Extension
18th Jan 20212:06 pmRNSSecond Price Monitoring Extn
18th Jan 20212:01 pmRNSPrice Monitoring Extension
14th Jan 20214:41 pmRNSSecond Price Monitoring Extn
14th Jan 20214:35 pmRNSPrice Monitoring Extension
14th Jan 20212:06 pmRNSSecond Price Monitoring Extn
14th Jan 20212:01 pmRNSPrice Monitoring Extension
14th Jan 20217:00 amRNSAppointment of new Vice President, Operations
8th Jan 202111:06 amRNSSecond Price Monitoring Extn
8th Jan 202111:00 amRNSPrice Monitoring Extension
30th Dec 202011:05 amRNSSecond Price Monitoring Extn
30th Dec 202011:00 amRNSPrice Monitoring Extension
29th Dec 20204:41 pmRNSSecond Price Monitoring Extn
29th Dec 20204:36 pmRNSPrice Monitoring Extension
3rd Nov 20207:00 amRNSAppointment of New Marketing and Sales Executive
28th Oct 20207:00 amRNSHalf Year Results
23rd Oct 20202:30 pmRNSResult of AGM
21st Oct 20207:00 amRNSNotice of Interim Results
13th Oct 202011:06 amRNSSecond Price Monitoring Extn
13th Oct 202011:00 amRNSPrice Monitoring Extension
2nd Oct 20204:35 pmRNSPrice Monitoring Extension
2nd Oct 20203:17 pmRNSCorrection to Full Year Results
30th Sep 20207:00 amRNSFull Year Results
16th Sep 20208:00 amRNSHolding(s) in Company
15th Sep 20207:00 amRNSNotice of Results
22nd Jul 20207:14 amRNSH1 2020 Trading Update
17th Jul 20201:36 pmRNSHolding(s) in Company
17th Jul 202011:18 amRNSHolding(s) in Company
15th Jul 20203:04 pmRNSDirector/PDMR Shareholding
14th Jul 202012:51 pmRNSResult of General Meeting
26th Jun 20206:01 pmRNSNotice of GM and Posting of Circular
24th Jun 20203:33 pmRNSResult of Fundraise
24th Jun 20207:55 amRNSClose of Accelerated Bookbuild
23rd Jun 20205:31 pmRNSLaunch of Fundraise

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.